Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder. Review uri icon

Overview

abstract

  • Attention-deficit/hyperactivity disorder (ADHD) significantly worsens quality of life and long-term functional outcomes in adults. Individual impairments in adults with ADHD can be further contextualized within considerable costs to society at large. Food and Drug Administration (FDA) approved stimulants and nonstimulant medications can significantly improve ADHD symptoms in adults. In the past 2 decades, the United States FDA has expanded approval of pharmacotherapeutic options for adult ADHD. However, limitations still persist in available psychotropics for certain patient populations such as those with comorbid substance use or cardiovascular illness. Clinicians therefore must appreciate several ongoing investigations into medications with unique mechanisms of action. This article reviews the current FDA approved and emerging medication options while providing guidelines for pharmacologic management of adult ADHD.

publication date

  • July 1, 2022

Research

keywords

  • Attention Deficit Disorder with Hyperactivity
  • Central Nervous System Stimulants
  • Substance-Related Disorders

Identity

Scopus Document Identifier

  • 85131796737

Digital Object Identifier (DOI)

  • 10.1016/j.chc.2022.03.008

PubMed ID

  • 35697401

Additional Document Info

volume

  • 31

issue

  • 3